People · Operator
Named in public records as an officer, director or promoter · active 2011–2012 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| VitaPath Genetics, Inc. | — | Biotechnology | Series A | $13.9M | $182.1M | 2012 |
| Chiron Guernsey Holdings L.P. Inc. | — | Other | Series A | $7.8M | $117.4M | 2011 |
Catherine M. Burzik at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Catherine M. Burzik on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Bruce Cohen | 1 | 7 |
| Rowan Chapman | 1 | 7 |
| Michael Borrus | 1 | 7 |
| Ali J. Satvat | 1 | 4 |
| Jasper Rine | 1 | 2 |
| Dennis Gilbert | 1 | 1 |
| Richard Taylor | 1 | 1 |
| Girish Putcha | 1 | 1 |
| John F. Megrue, Jr. | 1 | 1 |
| Erik J. Levy | 1 | 1 |
| Warren J. Roll | 1 | 1 |
| Jim A. Pittman | 1 | 1 |
| William J. Gumina | 1 | 1 |
| Jim J. Fasano | 1 | 1 |
| Steven J. Dyson | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.